Freenome, Inc.

Freenome, Inc. is a biotechnology company specializing in blood-based early cancer detection. Using a comprehensive multiomics platform that integrates molecular biology, computational biology, and machine learning, Freenome develops noninvasive screening tests based on a routine blood draw. Its technology analyzes a wide range of circulating biomarkers, including cell-free DNA, RNA, proteins, and immune-related signals, to identify cancer at its earliest, most treatable stages. Freenome focuses on next-generation diagnostics for cancers such as colorectal and other solid tumors, serving healthcare providers, health systems, and population health decision-makers with tools designed to improve cancer screening and precision oncology workflows. The company also engages in clinical research programs to support development, discovery, and validation of single-cancer and multi-cancer tests. Founded in 2014 and headquartered in Brisbane, California, Freenome plays a notable role in the life sciences and healthcare sectors as a provider of advanced cancer detection solutions powered by AI-driven genomics and multiomics analysis.

Sector

Financial Services

Industry

Shell Companies

CEO

Mr. Adam Leo Stone

Headquarters

New York, NY, United States

Website

www.perceptivelife.com